Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC.BCLI · Entity 7869 | Director | February 26, 2026 | May 20, 2026 |
| Zymeworks BC Inc.ZYME · Entity 12038 | Chief Scientific Officer | January 07, 2022 | January 07, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRAINSTORM CELL THERAPEUTICS INC.
Report date February 26, 2026 · Filed May 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.70 · Expires 2036-02-26 | Direct | 150,000 |
Reported balance
After 2026-02-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-26 · Grant · Acquired 150,000 · Balance 150,000 F1: Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan. F2: The Stock Options shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan.
F2: The Stock Options shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date.
Zymeworks BC Inc.
Report date January 07, 2022 · Filed January 07, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 36,407 |
Reported balance
After 2022-01-07 transaction · row 1
1 source rowRow 1 · 2022-01-07 · Grant · Acquired 74 · Balance 36,407 F1: Shares purchased pursuant to the Issuer's Amended and Restated Employee Stock Purchase Plan (ESPP) for the ESPP purchase period July 1, 2021 through December 31, 2021. In accordance with the ESPP, these shares were purchased at a price equal to 85% the closing price of the Issuer's common shares on December 31, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares purchased pursuant to the Issuer's Amended and Restated Employee Stock Purchase Plan (ESPP) for the ESPP purchase period July 1, 2021 through December 31, 2021. In accordance with the ESPP, these shares were purchased at a price equal to 85% the closing price of the Issuer's common shares on December 31, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2026 Filed May 20, 2026 22:06 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.70 Strike: $0.70 | $105,000.00 |
DisclosureSEC source: 0001104659-26-064657 · tm267728-5_4seq1.xml · derivative · entry 1 Polverino Anthony J. · CIK 0001729957 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2036-02-26 F1 · security: Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan. F1 · price: Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan. F2 · derivative.exercise_date: The Stock Options shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 22:34 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 24,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-000893 · tm251864-8_4seq1.xml · nonDerivative · entry 1 Polverino Anthony J. · CIK 0001729957 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,730 F1 · shares: Represents shares of restricted stock units ("RSUs") awarded under the 2014 Stock Incentive Plan. The RSUs shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date. F2 · balance_after: Reflects the Issuer's 1-for-15 reverse stock split effected market open on October 1, 2024. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:33 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 3,882 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-011390 · tm225365-1_4seq1.xml · nonDerivative · entry 1 Polverino Anthony J. · CIK 0001729957 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,960 F1 · shares: Shares acquired are shares of restricted stock awarded pursuant to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on March 1, 2022 until fully vested on the first anniversary of February 1, 2022, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each vesting date. Read SEC document |
| January 07, 2022 Filed Jan 7, 2022 21:30 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantCommon Shares | 74 | $13.94 | $1,031.56 |
DisclosureSEC source: 0000899243-22-001424 · doc4.xml · nonDerivative · entry 1 Polverino Anthony J. · CIK 0001729957 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,407 F1 · kind: Shares purchased pursuant to the Issuer's Amended and Restated Employee Stock Purchase Plan (ESPP) for the ESPP purchase period July 1, 2021 through December 31, 2021. In accordance with the ESPP, these shares were purchased at a price equal to 85% the closing price of the Issuer's common shares on December 31, 2021. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 22:03 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-151215 · tm2135659-4_4seq1.xml · nonDerivative · entry 1 Polverino Anthony J. · CIK 0001729957 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,078 F1 · shares: Shares acquired are shares of restricted stock awarded in connection with the Company's 2021 Annual Meeting of Stockholders pursuant to the Company's Second Amended and Restated Director Compensation Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on January 15, 2022 until fully vested on the first anniversary of December 15, 2021. Read SEC document |
| December 10, 2021 Filed Dec 11, 2021 01:03 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-148751 · tm2135032-6_4.xml · nonDerivative · entry 2 Polverino Anthony J. · CIK 0001729957 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,078 F2 · shares: Shares acquired are shares of restricted stock awarded in connection with the Company's 2020 Annual Meeting of Stockholders pursuant to the Brainstorm Cell Therapeutics Inc. Second Amended and Restated Director Compensation Plan . The shares of restricted stock vested in 12 consecutive, equal monthly installments commencing on December 11, 2020 until fully vested on the first anniversary of November 11, 2020, provided that the reporting person remained a director of Brainstorm Cell Therapeutics on each vesting date. Read SEC document |
| December 10, 2021 Filed Dec 11, 2021 01:03 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 2,216 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-148751 · tm2135032-6_4.xml · nonDerivative · entry 1 Polverino Anthony J. · CIK 0001729957 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,078 F1 · shares: Shares acquired are shares of restricted stock awarded pursuant to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on March 1, 2021 until fully vested on the first anniversary of February 1, 2021, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each vesting date. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 20:00 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,900 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0000899243-21-034985 · doc4.xml · derivative · entry 2 Polverino Anthony J. · CIK 0001729957 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,600 Underlying: Common Shares · 4,900 shares Expires 2028-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date of December 12, 2018, and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following first anniversary of grant date. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 20:00 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | Exercise / conversionCommon Shares | 4,900 | $15.00 | $73,500.00 |
DisclosureSEC source: 0000899243-21-034985 · doc4.xml · nonDerivative · entry 1 Polverino Anthony J. · CIK 0001729957 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 20:00 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantCommon Shares | 454 | $29.49 | $13,388.46 |
DisclosureSEC source: 0000899243-21-027914 · doc4.xml · nonDerivative · entry 1 Polverino Anthony J. · CIK 0001729957 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,433 F1 · kind: Shares purchased pursuant to the Issuer's Amended and Restated Employee Stock Purchase Plan (ESPP) for the ESPP purchase period January 1, 2021 through June 30, 2021. In accordance with the ESPP, these shares were purchased at a price equal to 85% the closing price of the Issuer's common shares on June 30, 2021. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 20:00 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantRestricted Stock Unit · Derivative | 8,125 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-011435 · doc4.xml · derivative · entry 5 Polverino Anthony J. · CIK 0001729957 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,125 Underlying: Common Shares · 8,125 shares Expires not disclosed F4 · derivative.exercise_price: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F7 · derivative.exercise_date: The RSUs vest in three equal annual installments beginning on March 10, 2022. F7 · derivative.expiration_date: The RSUs vest in three equal annual installments beginning on March 10, 2022. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 20:00 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantStock Option (Right to Buy) · Derivative | 48,750 | $0.00 Strike: $34.82 | $0.00 |
DisclosureSEC source: 0000899243-21-011435 · doc4.xml · derivative · entry 4 Polverino Anthony J. · CIK 0001729957 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,750 Underlying: Common Shares · 48,750 shares Expires 2031-03-09 F6 · derivative.exercise_date: Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following first anniversary of grant date. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 20:00 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | Exercise / conversionRestricted Stock Unit · Derivative | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-011435 · doc4.xml · derivative · entry 3 Polverino Anthony J. · CIK 0001729957 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Shares · 2,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F5 · derivative.exercise_date: The RSUs were granted on March 10, 2020 and vest in three equal annual instalments beginning on March 10, 2021. F5 · derivative.expiration_date: The RSUs were granted on March 10, 2020 and vest in three equal annual instalments beginning on March 10, 2021. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 20:00 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | SaleCommon Shares | 1,048 | $34.95 | $36,631.27 |
DisclosureSEC source: 0000899243-21-011435 · doc4.xml · nonDerivative · entry 2 Polverino Anthony J. · CIK 0001729957 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,979 F2 · kind: Represents common shares sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs. Pursuant to the terms of the applicable RSU grant agreement (the "Grant Agreement"), effective on the grant date of the RSUs, the Reporting Person irrevocably adopted a 10b5-1 plan pursuant to which the Reporting Person elected to sell shares to cover tax withholding obligations and other applicable fees in accordance with the terms of the Grant Agreement. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.80 to $35.15, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 20:00 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | Exercise / conversionCommon Shares | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-011435 · doc4.xml · nonDerivative · entry 1 Polverino Anthony J. · CIK 0001729957 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,027 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents common shares issued upon vesting of one third of the restricted stock units ("RSUs") granted on March 10, 2020. Read SEC document |
| January 07, 2021 Filed Jan 11, 2021 17:06 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantCommon Shares | 48 | $30.92 | $1,484.16 |
DisclosureSEC source: 0000899243-21-001344 · doc4.xml · nonDerivative · entry 1 Polverino Anthony J. · CIK 0001729957 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,527 F1 · kind: Shares purchased pursuant to the Issuer's Amended and Restated Employee Stock Purchase Plan (ESPP) for the ESPP purchase period July 1, 2020 through December 31, 2020. In accordance with the ESPP, these shares were purchased at a price equal to 85% the closing price of the Issuer's common shares on July 1, 2020. Read SEC document |
| July 02, 2020 Filed Jul 6, 2020 19:44 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantCommon Shares | 488 | $30.66 | $14,962.08 |
DisclosureSEC source: 0000899243-20-018549 · doc4.xml · nonDerivative · entry 1 Polverino Anthony J. · CIK 0001729957 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,479 F1 · kind: Shares purchased pursuant to the Issuer's Amended and Restated Employee Stock Purchase Plan (ESPP) for the ESPP purchase period January 1, 2020 through June 30, 2020. In accordance with the ESPP, these shares were purchased at a price equal to 85% the closing price of the Issuer's common shares on June 30, 2020. Read SEC document |
| March 10, 2020 Filed Mar 11, 2020 20:33 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantRestricted Stock Unit · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-008005 · doc4.xml · derivative · entry 2 Polverino Anthony J. · CIK 0001729957 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Shares · 7,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning on March 10, 2021. F3 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning on March 10, 2021. Read SEC document |
| March 10, 2020 Filed Mar 11, 2020 20:33 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $35.20 | $0.00 |
DisclosureSEC source: 0000899243-20-008005 · doc4.xml · derivative · entry 1 Polverino Anthony J. · CIK 0001729957 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Shares · 45,000 shares Expires 2030-03-09 F1 · derivative.exercise_date: Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following first anniversary of grant date. Read SEC document |
| February 01, 2020 Filed Feb 14, 2020 22:00 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 3,071 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-021983 · tm205737d3_4.xml · nonDerivative · entry 2 Polverino Anthony J. · CIK 0001729957 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,862 F2 · shares: Shares acquired are shares of restricted stock awarded on February 1, 2020 pursuant to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on March 1, 2020 until fully vested on the first anniversary of the date of grant, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each vesting date. Read SEC document |
| January 08, 2020 Filed Jan 9, 2020 16:06 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantCommon Shares | 371 | $19.54 | $7,249.34 |
DisclosureSEC source: 0000899243-20-000880 · doc4.xml · nonDerivative · entry 1 Polverino Anthony J. · CIK 0001729957 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,991 F1 · kind: Shares purchased pursuant to the issuer's Amended and Restated Employee Stock Purchase Plan (ESPP) for the ESPP purchase period July 1, 2019 through December 31, 2019. In accordance with the ESPP, these shares were purchased at a price equal to 85% the closing price of the issuer's common shares on July 1, 2019. Read SEC document |
| December 12, 2019 Filed Dec 13, 2019 16:17 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | Exercise / conversionStock Option (Right to Buy) · Derivative | 27,500 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0000899243-19-029160 · doc4.xml · derivative · entry 2 Polverino Anthony J. · CIK 0001729957 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,500 Underlying: Common Shares · 27,500 shares Expires 2028-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date of December 12, 2018, and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following first anniversary of grant date. Read SEC document |
| December 12, 2019 Filed Dec 13, 2019 16:17 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | Exercise / conversionCommon Shares | 27,500 | $15.00 | $412,500.00 |
DisclosureSEC source: 0000899243-19-029160 · doc4.xml · nonDerivative · entry 1 Polverino Anthony J. · CIK 0001729957 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,620 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 12, 2019 Filed Feb 14, 2020 22:00 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-021983 · tm205737d3_4.xml · nonDerivative · entry 1 Polverino Anthony J. · CIK 0001729957 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,791 F1 · shares: Shares acquired are shares of restricted stock awarded on December 12, 2019 pursuant to the Brainstorm Cell Therapeutics Inc. Second Amended and Restated Director Compensation Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on January 12, 2020 until fully vested on the first anniversary of the date of grant, provided that the reporting person remains a director (and committee member, as applicable) of Brainstorm Cell Therapeutics on each vesting date. Read SEC document |
| July 08, 2019 Filed Jul 10, 2019 16:55 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantCommon Shares | 1,120 | $12.49 | $13,988.80 |
DisclosureSEC source: 0000899243-19-019436 · doc4.xml · nonDerivative · entry 1 Polverino Anthony J. · CIK 0001729957 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,120 F1 · kind: Shares purchased pursuant to the issuer's Amended and Restated Employee Stock Purchase Plan (ESPP) for the ESPP purchase period January 1, 2019 through June 30, 2019. In accordance with the ESPP, these shares were purchased at a price equal to 85% the closing price of the issuer's common shares on January 2, 2019. Read SEC document |
| February 01, 2019 Filed Feb 22, 2019 22:00 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 3,501 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-009627 · tv514175_form4.xml · nonDerivative · entry 1 Polverino Anthony J. · CIK 0001729957 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,791 F1 · shares: Shares acquired are shares of restricted stock awarded on February 1, 2019 pursuant to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on March 1, 2019 until fully vested on the first anniversary of the date of grant, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each vesting date. Read SEC document |
| January 08, 2019 Filed Jan 10, 2019 16:23 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $15.53 | $0.00 |
DisclosureSEC source: 0000899243-19-000964 · doc4.xml · derivative · entry 1 Polverino Anthony J. · CIK 0001729957 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Shares · 75,000 shares Expires 2029-01-07 F1 · derivative.exercise_date: Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following first anniversary of grant date. Read SEC document |
| November 30, 2018 Filed Nov 30, 2018 22:05 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 1,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-062654 · tv507905_4.xml · nonDerivative · entry 2 Polverino Anthony J. · CIK 0001729957 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,290 Read SEC document |
| November 30, 2018 Filed Nov 30, 2018 22:05 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-062654 · tv507905_4.xml · nonDerivative · entry 1 Polverino Anthony J. · CIK 0001729957 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,623 F1 · shares: Shares acquired are shares of restricted stock awarded on November 30, 2018 pursuant to the Brainstorm Cell Therapeutics Inc. Second Amended and Restated Director Compensation Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on December 30, 2018 until fully vested on the first anniversary of the date of grant, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each vesting date. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 21:30 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 3,623 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-005728 · tv484711_4.xml · nonDerivative · entry 1 Polverino Anthony J. · CIK 0001729957 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,623 F1 · shares: Shares acquired are shares of restricted stock awarded on February 1, 2018 pursuant to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on March 1, 2018 until fully vested on the first anniversary of the date of grant, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.